UPCC 02419: An Open-label Single Arm Phase 2 | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

This research study is an open-label study designed to learn about the safety and effectiveness of an experimental drug called avapritinib (also known as BLU-285) when given to individuals who have been diagnosed with ASM, SM-AHN, or MCL. Experimental means that it is not yet known if this drug helps patients and is not available for sale. Open label means that you and your study doctor know you will receive avapritinib during the study. ASM, SM-AHN, or MCL (referred to as SM going forward) are disorders where abnormal mast cells accumulate in many organs and in bone marrow and cause abnormal organ function. Mast cells are a type of white blood cell that is part of the immune system. When increased in number or abnormal in function they release their contents resulting in allergic reactions and other related symptoms, which are also associated with mastocytosis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Advanced Systemic Mastocytosis
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 832566

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 02419: An Open-label Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients with Advanced Systemic Mastocytosis

Brief description of study

Eligibility of study

Find a site